Included with registration, selection made during registration process (non-cme events).


Tuesday, February 25, 7:00-8:15am (non-CME)

I5. Personalized Shock Therapy: The Role of Angiotensin II
Sponsored by La Jolla Pharmaceutical Company

Mark Williams, MD, FCCM, FCCP
Michelle Lim, PA-C

Thursday, February 27, 6:45-8:00am (non-CME)

I3. Hemoadsorption as Extracorporeal Organ Support (ECOS) to Regain Control in Critically Ill Patients – An Update
sponsored by CytoSorbents
Chairs: J Kellum/Pittsburgh/USA and P Honoré/Brussels/Belgium

J Kellum/Pittsburgh/USA
Scientific background and safety data

C Ince /Rotterdam/The Netherlands
Influence on microcirculation, endothelial function and outcome in septic shock patients

J Stange /Rostock/Germany
Detoxification and control of inflammation as key elements in liver support therapy


I4. The Hepatocyte Growth Factor/c-Met pathway and its Role in AKI
sponsored by Angion

1. Introduce the HGF/c-Met pathway, including its history and the emerging science regarding its role in tissue repair

2. Educate on the functions and the therapeutic potential of HGF/c-Met pathway in AKI

Prakash Narayan, PhD,
VP Preclinical Research, Angion

Tuesday, February 25 12:30 – 2:00pm (non-CME)

I1. Relevant Pathways, Novel Diagnostic and Therapeutic Approaches in Acute Organ Dysfunction
sponsored by Sphingotec

Recently discovered and well-known causes of acute organ dysfunction in critically ill patients will be the topic of this symposium, providing an overview of novel biomarkers for monitoring kidney function, endothelial function and DPP3 release. Beyond diagnostic use, these biomarkers have been identified as biotargets. Drug development aiming to modify relevant pathways leading to organ dysfunction is being carried out.

Moderators: Prof. Robert Christenson and Prof. Michael Joannidis

Relevant Pathways, Novel Diagnostic and Therapeutic Approaches in Acute Organ Dysfunction – Struck
Proenkephalin in critically ill patients – Beunders
A pivotal regulator and biotarget of vascular integrity and endothelial barrier function: Bioactive Adrenomedullin – Pickkers
Dipeptidyl peptidase 3, A protease at the core of a new disease mechanism – Legrand

Robert Christenson, MD
Michael Joannidis, MD
Peter Pickkers, MD
Matthieu Legrand, MD
Remi Beunders, MD
Joachim Struck, PhD

Wednesday, February 26 12:30 – 2:00pm (non-CME)

I2. Pathogen Reduction with a Novel Hemoperfusion Device: Seraph 100 (now CE marked)
sponsored by ExThera Medical

Development and History of Hemoperfusion Pathogen Reduction Device
Keith McCrea, CSO (ExThera Medical)

Clinical Need and Utilization
Professor Lakhmir Chawla MD (Veterans Affairs Medical Center, San Diego, CA)

Questions and Answers